Early Initiation of Tafolecimab for Patients With Acute Coronary Syndromeundergoing Percutaneous Coronary Intervention in Chinese Population

Conditions: Acute Coronary Syndrome; Non ST Segment Elevation Acute Coronary Syndrome Interventions: Drug: Tafolecimab; Drug: Cholesterol Absorption Inhibitor; Drug: Statin Sponsors: China National Center for Cardiovascular Diseases; Innovent Biologics, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials